---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011658"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:19:44.163667+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA denies approval of PTC Therapeutics' vatiquinone NDA for Friedreich's ataxia

## Summary
- FDA CRL states substantial evidence of efficacy not demonstrated; additional well-controlled study needed for resubmission.
- PTC plans to meet with FDA to discuss potential steps to address CRL issues.
- Vatiquinone was proposed for children and adults with Friedreich's ataxia.
- CEO Matthew B. Klein expressed disappointment but believes data support safe, effective therapy.

## SEC filing metadata
- accession: 0001558370-25-011658
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/0001558370-25-011658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/tmb-20250819x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011658
- JSON: https://secwatch.observer/filing/0001558370-25-011658.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.